Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Siemens Healthcare Diagnostics revealed its latest IVD solutions, including the Advia Centaur XPT Immunoassay System. Recently FDA-cleared, this high-throughput analyzer is designed to provide continuous operation and seamless connectivity, including to Aptio Automation. The XPT is not available in the U.S.
The family of Phadia instruments from Thermo Fisher Scientific now includes the Phadia 2500E Laboratory System for laboratories meeting high demands. Phadia Laboratory Systems are fully automated instruments for running assays that detect and quantitatively determine clinically relevant antibodies in the blood.
The BBI Group developed, in collaboration with the Defence Science and Technology Laboratory, a rapid test for Ebola that is in the process of being verified to allow EUA submission. Using lateral flow technology, BBI’s assay will make testing simpler and quicker than assays that require technical infrastructure.
Cepheid unveiled the GeneXpert Omni, a portable molecular diagnostics system enabling access to accurate, fast, and potentially life-saving diagnosis of tuberculosis, HIV, and Ebola in even the most remote areas of the world.
Medical Electronic Systems released its new automated sperm quality analyzer, the SQA-Vision. Developed based on 10 years of market feedback, the SQA-Vision is positioned to augment Medical Electronic’s line of SQA-V and QwikCheck semen analyzers with a top-of-the-line solution.
The Diatron Group displayed its new walkaway clinical chemistry analyzer, the Pictus P500. This medium-throughput system (215 tests per hour on a typical sample mix) is ergonomically designed and user-friendly. The advanced, intuitive Windows-based software and smart architecture means the P500 offers many features on an accessible platform including uninterrupted workflow, enhanced walkaway operation, and remote-access diagnostics.
Festo displayed the EXCM mini H-gantry, its high-speed automated handling system for clinical laboratories. The planar surface gantry system is fast, accurate, modular, and flexible. This plug-and-play system can be used for dosing, barcode-based sample identification, liquid dispensing/pipetting with the addition of a Z-axis, and more. The desktop system moves vials on a planar X/Y axis with absolute positioning accuracy.
Nuclea Biotechnologies will begin offering more than 50 research-use-only mass spectrometry–based biomarker tests as part of its laboratory services. The tests detect and quantify protein biomarkers in human serum or plasma and are available to pharmaceutical companies for clinical trials, to researchers, and as companion diagnostics.
Swisslog Healthcare Solutions announced the launch of its Nexus Station. As the next generation of pneumatic tube stations, the Nexus Station provides quiet delivery of PTS carriers and improved carrier management through a carousel that handles both send and receive actions.
Diadexus and Mayo Clinic signed an agreement to collaborate in the areas of education, research, and innovation on the PLAC Test for Lp-PLA2 Activity. The FDA-cleared test is used to identify risk for coronary heart disease in patients with no history of cardiovascular events.
